Clinical trial
The Safety of Intra-parenchymal Wharton Jelly Mesenchymal Stem Cell Injection in the Treatment of Diabetic Nephropathy
NCT03288571 is registered in ClinicalTrials.gov with Sophia Al-Adwan as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- The Safety of Intra-parenchymal Wharton Jelly Mesenchymal Stem Cell Injection in the Treatment of Diabetic Nephropathy
- Lead sponsor
- Sophia Al-Adwan
- Phase
- Phase 1/2
- Overall status
- Unknown status
- Start date
- November 30, 2019
- Completion date
- January 31, 2021
- Enrollment
- 20 (estimated)
- Sites
- Not reported
Conditions
As the registry lists them; a condition with its own page is linked.